泰恩康11月28日公告，公司全资子公司山东华铂凯盛生物科技有限公司于近日收到国家药品监督管理局 核准签发的巴瑞替尼片《药品注册证书》。巴瑞替尼是一种Janus 激酶（JAK）抑制剂，可阻断一种或 多种JAK 激酶家族成员的活性，从而抑制激活炎症的途径，由礼来制药公司和Incyte 合作开发。巴瑞替 尼最早于2017年在欧盟和英国上市，获批适应症为类风湿关节炎；2018年获得美国FDA批准被用于治疗 某些患有中度至重度活动性类风湿关节炎的成年患者，2022 年6 月，美国FDA批准了巴瑞替尼口服片剂 用于治疗患有严重斑秃的成年患者。该产品未来的具体销售情况可能受到行业政策、市场环境等因素影 响，具有不确定性。 ...

格隆汇11月28日丨泰恩康(301263.SZ)公布，全资子公司山东华铂凯盛生物科技有限公司于近日收到国 家药品监督管理局（简称"国家药监局"）签发的巴瑞替尼片《药品注册证书》。巴瑞替尼是一种Janus 激酶(JAK)抑制剂，可阻断一种或多种JAK激酶家族成员的活性，从而抑制激活炎症的途径，由礼来制 药公司和Incyte合作开发。 ...

Core Viewpoint - The company TianKang (301263.SZ) has received a drug registration certificate for Baricitinib tablets from the National Medical Products Administration, indicating a significant regulatory milestone for the company in the pharmaceutical sector [1] Group 1: Company Developments - TianKang's wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., has been granted the drug registration certificate for Baricitinib tablets [1] - Baricitinib is identified as a Janus kinase (JAK) inhibitor, which can block the activity of one or more members of the JAK kinase family, thereby inhibiting pathways that activate inflammation [1]

每经AI快讯，11月28日，泰恩康（301263）公告，公司全资子公司山东华铂凯盛生物科技有限公司收 到国家药品监督管理局签发的巴瑞替尼片《药品注册证书》。该产品用于治疗类风湿关节炎、严重斑秃 等。 ...

智通财经APP讯，泰恩康(301263.SZ)公告，公司全资子公司山东华铂凯盛生物科技有限公司于近日收到 国家药品监督管理局签发的巴瑞替尼片《药品注册证书》。巴瑞替尼是一种Janus激酶(JAK)抑制剂，可 阻断一种或多种JAK激酶家族成员的活性，从而抑制激活炎症的途径。 ...

证券代码：301263 证券简称：泰恩康 公告编号：2025-078 广东泰恩康医药股份有限公司 关于全资子公司收到巴瑞替尼片药品注册证书 的公告 广东泰恩康医药股份有限公司（以下简称"公司"）全资子公司山东华铂 凯盛生物科技有限公司于近日收到国家药品监督管理局（以下简称"国家药监 局"）签发的巴瑞替尼片《药品注册证书》。现将相关情况公告如下： 一、申请注册药品的基本情况 受理号：CYHS2302467 药品名称：巴瑞替尼片 剂型：片剂 规格：2mg 注册分类：化学药品 4 类 上市许可持有人：山东华铂凯盛生物科技有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本 品符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明 书、标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规 范要求方可生产销售。 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 药品批准文号：国药准字 H20256060 四、对公司的影响及风险提示 该产品未来的具体销售情况可能受到行业政策、市场环境等因素影响，具 有不确定性，敬请广大投资者审慎决 ...

公司治理方面，泰恩康构建了完善的现代企业治理结构，管理层坚守长期主义，股份解禁后无减持计 划，以实际行动彰显发展信心。同时，公司搭建全球化医药创新共享平台，通过内生增长与外延合作并 举，聚合外部研发力量，加速first-in-class创新药研发，CKBA软膏等项目进展顺利，展现了创新活力。 未来，泰恩康将以此次获奖为契机，持续深化ESG融入企业发展战略，在坚守医药企业社会责任、保障 产品质量安全的同时，加大创新药布局力度，完善研发梯队建设，以更优质的医药健康产品服务社会， 在可持续发展道路上稳步前行，为社会创造更大价值。 中证报中证网讯（ 王珞）11月26日，由中国证券报、中国国新主办，国新证券承办的2025金牛企业可 持续发展论坛暨第三届国新杯·ESG金牛奖颁奖典礼在苏州举行。泰恩康（301263）凭借在ESG领域的 卓越实践与快速成长，成功斩获"ESG新锐金牛奖二十强"殊荣。 作为聚焦医药健康领域的创新型企业，泰恩康的ESG实践始终紧扣行业特性，以"创新+责任"双轮驱动 发展。在环境维度，公司优化生产流程，推行绿色制造理念，从原材料采购到废弃物处理全链条把控环 保标准，助力医药行业低碳转型。社会价值层面 ...

Core Viewpoint - The stock of Taiankang has shown significant volatility, with a year-to-date increase of 100.53%, but recent trends indicate a decline over the past 20 and 60 days, raising concerns about its future performance [1][2]. Financial Performance - For the period from January to September 2025, Taiankang reported a revenue of 526 million yuan, representing a year-on-year decrease of 8.13% [2]. - The net profit attributable to the parent company for the same period was 31.41 million yuan, reflecting a substantial year-on-year decline of 73% [2]. Stock Market Activity - As of November 26, Taiankang's stock price was 29.66 yuan per share, with a market capitalization of 12.62 billion yuan [1]. - The trading volume on that day was 66.90 million yuan, with a turnover rate of 0.75% [1]. - The stock has experienced a net outflow of 4.76 million yuan in principal funds, indicating a lack of strong buying interest [1]. Shareholder Information - As of September 30, the number of shareholders for Taiankang increased to 12,000, a rise of 9.32% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 8.53% to 25,381 shares [2]. Dividend Distribution - Since its A-share listing, Taiankang has distributed a total of 460 million yuan in dividends, with 377 million yuan distributed over the past three years [3].

Core Viewpoint - The company, Tai En Kang, is poised to address a significant unmet clinical need in the treatment of pediatric vitiligo, with its innovative drug CKBA potentially becoming the first approved treatment for children aged 2-12 years [1] Group 1: Market Opportunity - There are currently no approved drugs for vitiligo in children aged 2-12 globally, and existing therapies are often used off-label [1] - The estimated number of vitiligo patients in China exceeds 30 million, with children accounting for approximately 32%-40% of this population, indicating a substantial market demand [1] - The annual treatment cost for pediatric vitiligo is estimated to be between 15,000 to 20,000 yuan, suggesting a market size exceeding 100 billion yuan [1] Group 2: Product Development - CKBA, derived from natural products like frankincense, is a new immunomodulator that offers greater targeting and safety compared to traditional immunosuppressants, making it particularly suitable for pediatric use [1] - The company anticipates that CKBA cream could be approved as the first innovative drug for treating vitiligo in children aged 2-12, and it is expected to become the preferred option for maintenance therapy [1] - Projections indicate that, once approved, the annual peak sales for CKBA in the pediatric vitiligo market could exceed 5 billion yuan [1] Group 3: Regulatory Progress - On November 20, the company announced that its subsidiary, Bo Chuang Yuan, has had the application for CKBA cream (Class 1 chemical drug) for pediatric vitiligo Phase II clinical trials accepted by the National Medical Products Administration [1]

Group 1 - The core viewpoint of the article highlights that TianKang (SZ 301263) will hold an investor meeting on November 21, 2025, where the company's Vice President and Secretary of the Board, Li Ting, will address investor inquiries [1] - For the year 2024, TianKang's revenue composition is as follows: 61.1% from pharmaceutical agency, 37.28% from pharmaceutical manufacturing, 1.51% from pharmaceutical technology services, and 0.12% from other businesses [1] - As of the report, TianKang's market capitalization stands at 12.1 billion yuan [1]